Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: Results of the Champion study

Therapeutic Advances in Cardiovascular Disease

Volumn 8, Issue 1, 2014, Pages 12-21

  Punzi, Henry A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

ambulatory blood pressure; angiotensin receptor blocker; antihypertensives; olmesartan amlodipine hydrochlorothiazide

Indexed keywords

AMBULATORY BLOOD PRESSURE; ANGIOTENSIN RECEPTOR BLOCKER; ANTIHYPERTENSIVES; OLMESARTAN/AMLODIPINE/HYDROCHLOROTHIAZIDE;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES; TREATMENT OUTCOME;

AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS OLMESARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MONOTHERAPY; OPEN STUDY; OUTPATIENT DEPARTMENT; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 84893549866     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944713520062     Document Type: Article

References (23)

1. Chrysant S. Melino M. Karki S. Lee J. Heyrman R. (2008) The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 30: 587–604.
2. Egan B. Zhao Y. Axon R. (2010) US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. J Am Med Assoc 303: 2043–2050.
3. Giles T. Oparil S. Silfani T. Wang A. Walker J. (2007) Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 9: 187–195.
4. Guo G. He D. Zhend W. Walton G. (2012) Trends in prevalance, awareness, management and control of hypertension among United States adults 1999–2010. J Am Coll Cardiol 10: 1016.
5. Iskedjian M. Einarson T. MacKeigan L. Shear N. Addis A. Mittmann N. et al. (2002) Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 24: 302–316.
6. Israili Z. (2000) Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 14(Suppl. 1): S73–S86.
7. Kereiakes D. Neutel J. Punzi H. Xu J. Lipka L. Dubiel R. (2007) Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs 7: 361–372.
8. Le M. Pugsley M. Vauquelin G. van Liefde I. (2007) Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT 1 receptor. Br J Pharmacol 151: 952–962.
9. Lewington S. Clarke R. Qizilbash N. Peto R. Collins R. Studies Collaboration (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903–1913.
10. Oparil S. Melino M. Lee J. Fernandez V. Heyrman R. (2010) Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 32: 1252–1269.
11. Oparil S. Silfani T. Walker J. (2005) Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens 18: 287–294.
12. Oparil S. Williams D. Chrysant S. Marbury T. Neutel J. (2001) Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 3: 283–291.
13. Pickering T. Hall J. Appel L. Falkner B. Graves J. Hill M. et al. (2005) Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 111: 697–716.
14. Punzi H. (1998) Why ambulatory blood pressure monitoring? Am J Health-Syst Pharmacy 55: S12–S16.
15. Punzi H. (2009) Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Exp Rev Cardiovasc Ther 7: 229–239.
16. Punzi H. (2011) Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination. Integ Blood Press Control 4: 73–83.
17. Punzi H. Lewin A. Wei L. Chavanu K. (2012 a) Efficacy / safety of olmesartan medoxomil versus losartan potassium in naive versus previously treated subjects with hypertension. Adv Ther 29: 524–537.
18. Punzi H. Neutel J. Kereiakes D. Shojaee A. Waverczak W. Dubiel R. et al. (2010) Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: The AZOR trial evaluating blood pressure reductions and control (AZTEC) study. Ther Adv Cardiovasc Dis 4: 209–221.
19. Punzi H. Novrit B. Trandolapril / Verapamil Multicenter Study Group (1997) The treatment of severe hypertension with trandolapril, verapamil, and hydrochlorothiazide. J Human Hypertens 11: 477–481.
20. Punzi H. Punzi C. (2004) Metabolic issues in the antihypertensive and lipid-lowering heart attack trial study. Curr Hypertens Rep 6: 106–110.
21. Punzi H. Punzi C. (2006) A Probe forced-titration trial to compare trandolapril / verapamil and benazepril / amlodipine for the control of stage I-II hypertension utilizing ambulatory blood pressure monitoring. J Clin Hypertens 8: A56–A57.
22. Punzi H. Shojaee A. Maa J. BP-CRUSH Investigators (2012 b) Efficacy and tolerability of fixed-dose amlodipine / olmesartan medoxomil with or without hydrochlorothiazide in Hispanic and non-Hispanic patients whose blood pressure is uncontrolled on antihypertensive monotherapy. Ther Adv Cardiovasc Dis 6: 149–161.
23. Weir M. Punzi H. Flack J. Stoakes K. Chavanu K. Li W. et al. (2011) A randomized, double-blind, forced titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension. Postgrad Med 123: 80–87.